Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patisiran in TTR Amyloidosis
NCT01617967Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- May 2012
- Primary completion
- Oct 2013
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 7
01
Overview
A Phase 2 trial of patisiran in transthyretin amyloidosis (ATTR), sponsored by Alnylam Pharmaceuticals. Started May 2012; status: completed.
02
Drugs
patisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT01617967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01617967.